39
Participants
Start Date
March 8, 2011
Primary Completion Date
February 2, 2022
Study Completion Date
February 2, 2022
Vigil™
Vigil is composed of autologous tumor cells harvested from the patient at the time of initial de-bulking surgery which are then transfected extracorporeally, with a plasmid encoding for the gene for GM-CSF, an immune-stimulatory cytokine, and a bifunctional, short hairpin RNA which specifically knocks down the expression of furin, the critical convertase responsible for production of the two TGβ isoforms.
Florida Cancer Specialists, West Palm Beach
Mary Crowley Cancer Research Centers, Dallas
Texas Oncology - Sammons Cancer Center, Dallas
Texas Oncology - Fort Worth, Fort Worth
Cancer Care Northwest, Spokane
Dartmouth-Hitchcock Medical Center/Norris Cotton Cancer Center, Lebanon
Hackensack University Medical Center, Hackensack
Lead Sponsor
Gradalis, Inc.
INDUSTRY